CXCR7 ameliorates myocardial infarction as a β-arrestin-biased receptor
Open Access
- 9 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-12
- https://doi.org/10.1038/s41598-021-83022-5
Abstract
Most seven transmembrane receptors (7TMRs) are G protein-coupled receptors; however, some 7TMRs evoke intracellular signals through β-arrestin as a biased receptor. As several β-arrestin-biased agonists have been reported to be cardioprotective, we examined the role of the chemokine receptor CXCR7 as a β-arrestin-biased receptor in the heart. Among 510 7TMR genes examined, Cxcr7 was the most abundantly expressed in the murine heart. Single-cell RNA-sequencing analysis revealed that Cxcr7 was abundantly expressed in cardiomyocytes and fibroblasts. Cardiomyocyte-specific Cxcr7 null mice showed more prominent cardiac dilatation and dysfunction than control mice 4 weeks after myocardial infarction. In contrast, there was no difference in cardiac phenotypes between fibroblast-specific Cxcr7-knockout mice and control mice even after myocardial infarction. TC14012, a specific agonist of CXCR7, significantly recruited β-arrestin to CXCR7 in CXCR7-expressing cells and activated extracellular signal-regulated kinase (ERK) in neonatal rat cardiomyocytes. Cxcr7 expression was significantly increased and ERK was activated in the border zone of the heart in control, but not Cxcr7 null mice. These results indicate that the abundantly expressed CXCR7 in cardiomyocytes may play a protective role in the heart as a β-arrestin-biased receptor and that CXCR7 may be a novel therapeutic target for myocardial infarction.Funding Information
- Japan Society for the Promotion of Science (JP 19J13042, 19K08510, 19H03649)
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Takeda Science Foundation
- SENSHIN Medical Research Foundation
- Bayer Academic Support
- British Heart Foundation (CH/11/3/29051)
- Japan Agency for Medical Research and Development (JP20gm0810013)
This publication has 63 references indexed in Scilit:
- Molecular Basis for CCRL2 Regulation of Leukocyte MigrationFrontiers in Cell and Developmental Biology, 2020
- Cardiac natriuretic peptidesNature Reviews Cardiology, 2020
- Different contributions of chemokine N‐terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3British Journal of Pharmacology, 2018
- Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signalingNature Communications, 2017
- A new inhibitor of the β-arrestin/AP2 endocytic complex reveals interplay between GPCR internalization and signallingNature Communications, 2017
- Fibronectin Is Essential for Reparative Cardiac Progenitor Cell Response After Myocardial InfarctionCirculation Research, 2013
- The chemokine receptor CXCR7 functions to regulate cardiac valve remodelingDevelopmental Dynamics, 2011
- Regulation of Expression of Stromal-Derived Factor-1 Receptors: CXCR4 and CXCR7 in Human RhabdomyosarcomasMolecular Cancer Research, 2010
- A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signalingProceedings of the National Academy of Sciences of the United States of America, 2007
- A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor developmentThe Journal of Experimental Medicine, 2006